المؤلفون: Pardis Mirzaeyan, Mohammad Shokrzadeh, Ali Salehzadeh, Farzam Ajamian

المصدر: Journal of Mazandaran University of Medical Sciences, Vol 33, Iss 230, Pp 50-69 (2024)

مصطلحات موضوعية: single nucleotide polymorphism, breast cancer, esr1 gene, rflp-pcr, rs2234693, mirna, cerna network, Medicine, Medicine (General), R5-920

وصف الملف: electronic resource

العلاقة: http://jmums.mazums.ac.ir/article-1-20350-en.pdfTest; https://doaj.org/toc/1735-9260Test; https://doaj.org/toc/1735-9279Test

الوصول الحر: https://doaj.org/article/bca6d4a5f75f4b41a7c98a4109b4cfabTest

المؤلفون: Mueller, S.H., Augustinsson, A., Olsson, H., Kuchenbaecker, Karoline B.

المصدر: Genome Medicine EpiHealth: Epidemiology for Health. 15(1)

مصطلحات موضوعية: Breast cancer susceptibility, Diverse ancestry, Gene regulation, Genome-wide association study, Rare variants, African, ancestry group, Article, Asian, boredom susceptibility, breast cancer, cancer prognosis, CBLB gene, cohort analysis, controlled study, ESR1 gene, European, FGFR2 gene, FMNL3 gene, gene base aggregation, gene expression level, gene structure, genetic association, genetic association study, genetic code, genetic variability, Hispanic, human, human cell, human tissue, LSP1 gene, major clinical study, MAP3K1 gene, meta analysis (topic), South and Central America, SRGAP2C gene, statistical significance, tumor-related gene, Black person, breast tumor, female, genetic predisposition, genetic screening, genetics, genome-wide association study, meta analysis, procedures, single nucleotide polymorphism, FMNL3 protein, methenamine, Black People, Breast Neoplasms, Female, Formins, Genetic Predisposition to Disease, Genetic Testing, Genome-Wide Association Study, Humans, Polymorphism, Single Nucleotide, Medicin och hälsovetenskap, Medicinska och farmaceutiska grundvetenskaper, Medicinsk genetik, Medical and Health Sciences, Basic Medicine, Medical Genetics, Klinisk medicin, Cancer och onkologi, Clinical Medicine, Cancer and Oncology

الوصول الحر: https://lup.lub.lu.se/record/03b290d6-d650-490a-9e52-2fcb867a25b3Test
http://dx.doi.org/10.1186/s13073-022-01152-5Test

المؤلفون: Margaux Betz, Vincent Massard, Pauline Gilson, Andréa Witz, Julie Dardare, Alexandre Harlé, Jean-Louis Merlin

المصدر: Cancers, Vol 15, Iss 21, p 5169 (2023)

مصطلحات موضوعية: endocrine therapy, breast cancer, liquid biopsy, ESR1 gene, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/15/21/5169Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/baba77557d4a4305b99fd1ab01e3d623Test

المؤلفون: N. Sivaranjani, Swaathy Ramamurthy, Prathibhabharathi, M. Rasheed Khan

مصطلحات موضوعية: myocardial infarction, Coronary artery disease, ESR1 gene polymorphisms

العلاقة: https://dx.doi.org/10.5281/zenodo.12514034Test

الإتاحة: https://doi.org/10.5281/zenodo.1251403510.5281/zenodo.12514034Test

المؤلفون: Betz, Margaux, Massard, Vincent, Gilson, Pauline, Witz, Andréa, Dardare, Julie, Harlé, Alexandre, Merlin, Jean-Louis

المساهمون: Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de Lorraine - Alexis Vautrin Nancy (UNICANCER/ICL), UNICANCER

المصدر: ISSN: 2072-6694.

مصطلحات موضوعية: endocrine therapy, breast cancer, liquid biopsy, ESR1 gene, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]

العلاقة: hal-04295094; https://hal.science/hal-04295094Test; https://hal.science/hal-04295094/documentTest; https://hal.science/hal-04295094/file/cancers-15-05169.pdfTest

الإتاحة: https://doi.org/10.3390/cancers15215169Test
https://hal.science/hal-04295094Test
https://hal.science/hal-04295094/documentTest
https://hal.science/hal-04295094/file/cancers-15-05169.pdfTest

المؤلفون: Tarasenko, T.Ye.

المصدر: Ukrainian Journal of Radiology and Oncology; Vol. 30 No. 2 (2022): Ukrainian Journal of Radiology and Oncology; 50-61 ; Український радіологічний та онкологічний журнал; Том 30 № 2 (2022): Український радіологічний та онкологічний журнал; 50-61 ; 2708-7174 ; 2708-7166 ; 10.46879/ukroj.2.2022

مصطلحات موضوعية: metastatic breast cancer, hormone therapy, aromatase inhibitors, resistance, ESR1 gene polymorphisms, метастатичний рак грудної залози, гормонотерапія, інгібітори ароматази, резистентність, поліморфізми гена ESR1

وصف الملف: application/pdf

العلاقة: https://ukroj.com/index.php/journal/article/view/155/88Test; https://ukroj.com/index.php/journal/article/view/155Test

الإتاحة: https://doi.org/10.46879/ukroj.2.2022.50-61Test
https://doi.org/10.46879/ukroj.2.2022Test
https://ukroj.com/index.php/journal/article/view/155Test

المؤلفون: Ana Canadas-Sousa, Marta Santos, Bárbara Leal, Rui Medeiros, Patrícia Dias-Pereira

المصدر: BMC Veterinary Research, Vol 15, Iss 1, Pp 1-10 (2019)

مصطلحات موضوعية: Canine mammary tumors, ESR1 gene, SNP, Genetic profile, Veterinary medicine, SF600-1100

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12917-019-2062-yTest; https://doaj.org/toc/1746-6148Test

الوصول الحر: https://doaj.org/article/e3e7b7cd3c864a74be7210516c78d400Test

المؤلفون: Vladimira Mondockova, Maria Adamkovicova, Martina Lukacova, Birgit Grosskopf, Ramona Babosova, Drahomir Galbavy, Monika Martiniakova, Radoslav Omelka

المصدر: BMC Medical Genetics, Vol 19, Iss 1, Pp 1-13 (2018)

مصطلحات موضوعية: Osteoporosis, ESR1 gene, Polymorphisms, BMD, Fractures, HT, Internal medicine, RC31-1245, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12881-018-0684-8Test; https://doaj.org/toc/1471-2350Test

الوصول الحر: https://doaj.org/article/9787fffc55654396bc3417e9d91a821dTest

المؤلفون: Ramirez, Karla, Fernández, Rosa, Collet, Sarah, Kiyar, Meltem, Delgado-Zayas, Enrique, Gómez-Gil, Esther, Van Den Eynde, Tibbert, T'Sjoen, Guy, Guillamon, Antonio, Müller, Sven, Pásaro, Eduardo

المصدر: FRONTIERS IN NEUROSCIENCE ; ISSN: 1662-453X

مصطلحات موضوعية: Medicine and Health Sciences, General Neuroscience, DNA methylation, epigenetics, gender dysphoria, gender identity, gender incongruence, ESTROGEN-RECEPTOR-ALPHA, HORMONE-THERAPY, ESR1 GENE, BRAIN, ANDROGEN, PROMOTER, POLYMORPHISM, DIFFERENTIATION, MASCULINIZATION

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/8743655Test; http://hdl.handle.net/1854/LU-8743655Test; http://dx.doi.org/10.3389/fnins.2021.701017Test; https://biblio.ugent.be/publication/8743655/file/8743658Test

الإتاحة: https://doi.org/10.3389/fnins.2021.701017Test
https://biblio.ugent.be/publication/8743655Test
http://hdl.handle.net/1854/LU-8743655Test
https://biblio.ugent.be/publication/8743655/file/8743658Test

المؤلفون: E. Shestakova A., Е. Шестакова А.

المصدر: Advances in Molecular Oncology; Том 8, № 1 (2021); 10-16 ; Успехи молекулярной онкологии; Том 8, № 1 (2021); 10-16 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2021-8-1

مصطلحات موضوعية: ESR1 gene, LYN gene, mutation, prognosis, ovarian cancer, resistance, estrogen receptor α, LYN kinase, endocrine therapy, ген ESR1, ген LYN, мутация, прогноз, рак яичников, резистентность, эстрогеновый рецептор α, киназа LYN, эндокринная терапия

وصف الملف: application/pdf

العلاقة: https://umo.abvpress.ru/jour/article/view/327/219Test; Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011;62:233–47. PMID: 20887199. DOI:10.1146/annurevmed-070909-182917.; Haque M.M., Desai K.V. Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol (Lausanne) 2019;10:573. PMID: 31496995. DOI:10.3389/fendo.2019.00573.; Tebbit C.L., Bentley R.C., Olson J.A. Jr. et al. Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer 2004;40(1):51–4. PMID: 15034868. DOI:10.1002/gcc.20017.; Toy W., Shen Y., Won H. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45(12):1439–45. PMID: 24185512. DOI:10.1038/ng.2822.; Martin L.A., Ribas R., Simigdala N. et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun 2017;8(1):1865. PMID: 29192207. DOI:10.1038/s41467-017-01864-y.; Harrod A., Fulton J., Nguyen V.T.M. et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene 2017;36(16): 2286–96. PMID: 27748765. DOI:10.1038/onc.2016.382.; Toy W., Weir H., Razavi P. et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov 2017;7(3):277–87. PMID: 27986707. DOI:10.1158/2159-8290.CD-15-1523.; Stover E.H., Feltmate C., Berkowitz R.S. et al. Targeted next-generation sequencing reveals clinically actionable BRAF and ESR1 mutations in low-grade serous ovarian carcinoma. JCO Precis Oncol 2018;2:1–12. PMID: 30828692. DOI:10.1200/PO.18.00135.; Gaillard S.L., Andreano K.J., Gay L.M. et al. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol 2019;154(1):199–206. PMID: 30987772. DOI:10.1016/j.ygyno.2019.04.010.; Schwarz L.J., Fox E.M., Balko J.M. et al. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest 2014;124(12):5490–502. PMID: 25401474. DOI:10.1172/JCI72573.; Ellis M.J., Ding L., Shen D. et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486(7403):353–60. PMID: 22722193. DOI:10.1038/nature11143.; Ishizawar R., Parsons S.J. c-Src and cooperating partners in human cancer. Cancer Cell 2004;6(3):209–14. PMID: 15380511. DOI:10.1016/j. ccr.2004.09.001.; Fox E.M., Andrade J., Shupnik M.A. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009;74(7):622–7. PMID: 18996136. DOI:10.1016/j.steroids.2008.10.014.; Sun J., Zhou W., Kaliappan K. et al. ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. Mol Endocrinol 2012;26(9):1567–77. PMID: 22865929. DOI:10.1210/me.2012-1140.; Тюляндин С.А., Коломиец Л.А., Морхов К.Ю. и др. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные опухоли: Практические рекомендации RUSSCO 2019;9(3s2):164–76.; Colombo N., Sessa C., du Bois A. et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019;30(5):672–705. PMID: 31046081. DOI:10.1093/annonc/mdz062.; Bowman A., Gabra H., Langdon S.P. et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8(7):2233–9. PMID: 12114425.; Smyth J.F., Gourley C., Walker G. et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007;13(12): 3617–22. PMID: 17575226. DOI:10.1158/1078-0432.CCR-06-2878.; Gershenson D.M., Sun C.C., Iyer R.B. et al. Hormonal therapy for recurrent lowgrade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012;125(3):661–6. PMID: 22406638. DOI:10.1016/j.ygyno.2012.02.037.; Fader A.N., Bergstrom J., Jernigan A. et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival? Gynecol Oncol 2017;147(1):85–91. PMID: 28768570. DOI:10.1016/j.ygyno.2017.07.127.; McIntyre J.B., Rambau P.F., Chan A. et al. Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma. Histopathology 2017;70(3):347–58. PMID: 27575406. DOI:10.1111/his.13071.; The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353):609–15. PMID: 21720365. DOI:10.1038/nature10166.; Robertson J.F., Evans A., Henschen S. et al. A randomized, open-label, presurgical, window of opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2– primary breast cancer. Clin Cancer Res 2020;26(16):4242–9. PMID: 32234755. DOI:10.1158/1078-0432.CCR-19-3387.; Weir H.M., Bradbury R.H., Lawson M. et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Res 2016;76(11):3307–18. PMID: 27020862. DOI:10.1158/0008-5472.CAN-15-2357.; Choi Y.L., Bocanegra M., Kwon M.J. et al. LYN is a mediator of epithelialmesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010;70(6):2296–306. PMID: 20215510. DOI:10.1158/0008-5472.CAN-09-3141.; Roskoski R. Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res 2015;94:9–25. PMID: 25662515. DOI:10.1016/j.phrs.2015.01.003.; Greif P.A., Yaghmaie M., Konstandin N.P. et al. Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia 2011;25(9):1519–22. PMID: 21606962. DOI:10.1038/leu.2011.114.; Xu P.P., Zhong H.J., Huang Y.H. et al. Bcell function gene mutations in diffuse large B-cell lymphoma: a retrospective cohort study. EBioMedicine 2017;16:106–14. PMID: 28153771. DOI:10.1016/j.ebiom.2017.01.027.; Suresh P.S., Ma S., Migliaccio A., Chen G. Protein-tyrosine phosphatase H1 increases breast cancer sensitivity to antiestrogens by dephosphorylating estrogen receptor at Tyr537. Mol Cancer Ther 2014;13(1):230–8. PMID: 24227889. DOI:10.1158/1535-7163.MCT-13-0610.; Montero J.C., Seoane S., Ocana A. et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011;17(17):5546–52. PMID: 21670084. DOI:10.1158/1078-0432.CCR-10-2616.; Hiscox S., Morgan L., Green T., Nicholson R.I. Src as a therapeutic target in antihormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006; 13(Suppl. 1):53–9. PMID: 17259559. DOI:10.1677/erc.1.01297.; Riggins R.B., Thomas K.S., Ta H.Q. et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006;66(14):7007–15. PMID: 16849545. DOI:10.1158/0008-5472.CAN-05-3952.; Konecny G.E., Glas R., Dering J. et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 2009;101(10):1699–708. PMID: 19861960. DOI:10.1038/sj.bjc.6605381.; Mayer E.L., Baurain J.F., Sparano J. et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011;17(21):6897–904. PMID: 21903773. DOI:10.1158/1078-0432.CCR-11-0070.; Hiscox S., Morgan L., Green T.P. et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97(3):263–74. PMID: 16333527. DOI:10.1007/s10549-005-9120-9.; Chen Y., Guggisberg N., Jorda M. et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009;15(10):3396–405. PMID: 19451593. DOI:10.1158/1078-0432.CCR-08-3127.; Chen Y., Alvarez E.A., Azzam D. et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat 2011;128(1):69–78. PMID: 20669046. DOI:10.1007/s10549-010-1024-7.; Hiscox S., Jordan N.J., Smith C. et al. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 2009;115(1):57–67. PMID: 18493848. DOI:10.1007/s10549-008-0058-6.; https://umo.abvpress.ru/jour/article/view/327Test

الإتاحة: https://doi.org/10.17650/2313-805X-2021-8-1-10-16Test
https://doi.org/10.17650/2313-805X-2021-8-1Test
https://doi.org/10.1146/annurevmed-070909-182917Test
https://doi.org/10.3389/fendo.2019.00573Test
https://doi.org/10.1002/gcc.20017Test
https://doi.org/10.1038/ng.2822Test
https://doi.org/10.1038/s41467-017-01864-yTest
https://doi.org/10.1038/onc.2016.382Test
https://doi.org/10.1158/2159-8290.CD-15-1523Test
https://doi.org/10.1200/PO.18.00135Test